Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
  • inderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Följda bolag
    • Teamet

Du verkar använda en bredare skärm. Vill du aktivera en bredare visningsupplevelse på denna sida?

Zerion Pharma – Regulatory environment and strategic partnerships

Av HC Andersen Capital
Zerion Pharma

Meet Zerion Pharma’s management and regulatory team – CEO Ole Wiborg, CFO Jakob Dynnes Hansen, and Mónica González VP Regulatory Affairs. Management will briefly run through the investment proposal and business case. Then management will focus on the regulatory environment governing the Dispersome™ technology, formulation of new drugs, and reformulation of existing drugs. Last but not least CEO Ole Wiborg will give a little flavor on the company’s strategic partnerships.

Zerion Pharma is a non-listed Danish company seeking €2-3m in a private placement round.

The company aims to make a real difference in health care with its Dispersome™ technology in relation to the formulation of new and existing drugs. Poor drug solubility is one of the main reasons for drug development failure. ZERION has a solution - Dispersome® - a technology that increases the chance of success for new drug development, allows for improvement of existing drugs enabling more new drugs to reach the market and leads to improved treatment of patients as well as reduced toxic waste. The Dispersome® technology makes it possible to reduce the number of active drugs by up to 75%.

Disclaimer: HC Andersen Capital receives payment from Zerion Pharma for a Digital IR/Corporate Visibility agreement. Zerion Pharma is a private company (i.e. not listed on a regulated stock market). Investors should therefore be aware of the potential risks that can be associated with investing in a private company, including liquidity conditions, how shares are traded as well as the process of the specific capital raise. /Claus Thestrup 9.49 PM 09-02-2023.

A recording of the event will be available per request. Please contact mie@hcandersencapital.dk to know more.

Recent videos

UPM and Sappi are planning a joint venture in graphic papers
04.12.2025 klo 14.00 UPM-Kymmene
GreenMobility: How far away are driverless cars in Denmark
04.12.2025 klo 12.32 GreenMobility
Systemair, Audiocast, Q2'25/26
04.12.2025 klo 10.00 Systemair
Hafnia – Presentation of the quarterly report for Q3 2025
02.12.2025 klo 12.00 Hafnia
Admicom Capital Markets Day 2025
02.12.2025 klo 10.00 Admicom
Titta på alla videos
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.